Payment overview · 2025
General Payments
$23,580.32
249 reported records · 18 companies
Healthcare provider profile · identity verified
Daria Lewis, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CARY, NC · NPI 1316373475
Verified facts
What the public records show
CMS Open Payments records show Daria Lewis, FNP received $23,580.32 in general payments during 2025 across 249 reported records.
Alkermes, Inc. accounted for 80.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Caplyta, Fanapt, Invega Sustenna, Loreev Xr, Lybalvi, Rexulti, Vraylar, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Lybalvi by this doctor in 2024.
Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Loreev Xr by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Invega Trinza by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rexulti by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Zubsolv by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rexulti by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18,926.82 | 80.3% | 56 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $726.59 | 3.1% | 24 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $704.26 | 3.0% | 36 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $637.29 | 2.7% | 28 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $608.40 | 2.6% | 16 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $575.09 | 2.4% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $446.99 | 1.9% | 26 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $276.41 | 1.2% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $256.62 | 1.1% | 17 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $166.01 | 0.7% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.73 | 0.4% | 4 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $43.09 | 0.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.74 | 0.1% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $26.59 | 0.1% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $18.81 | 0.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.64 | 0.1% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $14.14 | 0.1% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $14.10 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,925.00 | 9 |
| Food and Beverage | $5,492.03 | 222 |
| Consulting Fee | $4,380.00 | 2 |
| Travel and Lodging | $1,783.29 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18,909.88 | 55 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $726.59 | 24 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $704.26 | 36 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $608.40 | 16 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $575.09 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $479.73 | 24 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $446.99 | 26 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $387.82 | 18 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $269.83 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $256.62 | 17 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $193.37 | 6 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $166.01 | 7 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $164.27 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $155.41 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $121.00 | 8 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $43.09 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 48 | exact normalized | Medicare Part D |
| LOREEV XR loreev xr |
2025 | Loreev Xr | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 155 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 161 | exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
161 | 17 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
155 | 21 |
| Almatica Pharma LLC Exact reporting entity; no affiliate inference |
2025 | LOREEV XR open payments reported associated product |
CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018 |
Loreev Xr · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 482 | 78 |
| Benztropine Mesylate | Benztropine Mesylate | 404 | 59 |
| Aripiprazole | Aripiprazole | 300 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 298 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 275 | 53 |
| Risperidone | Risperidone | 271 | 39 |
| Olanzapine | Olanzapine | 259 | 31 |
| Clonazepam | Clonazepam | 233 | 30 |
| Divalproex Sodium Er | Divalproex Sodium | 230 | 24 |
| Clozapine | Clozapine | 221 | 14 |
| Divalproex Sodium | Divalproex Sodium | 200 | 21 |
| Lamotrigine | Lamotrigine | 183 | 24 |
| Bupropion Xl | Bupropion Hcl | 175 | 22 |
| Gabapentin | Gabapentin | 173 | 29 |
| Buspirone Hcl | Buspirone Hcl | 165 | 25 |
| Vraylar | Cariprazine Hcl | 161 | 17 |
| Lybalvi | Olanzapine/Samidorphan Malate | 155 | 21 |
| Sertraline Hcl | Sertraline Hcl | 135 | 23 |
| Haloperidol | Haloperidol | 130 | 16 |
| Lithium Carbonate Er | Lithium Carbonate | 106 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 99 | suppressed |
| Lorazepam | Lorazepam | 94 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 87 | 11 |
| Prazosin Hcl | Prazosin Hcl | 87 | 14 |
| Ziprasidone Hcl | Ziprasidone Hcl | 87 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 83 | 17 |
| Lithium Carbonate | Lithium Carbonate | 80 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | suppressed |
| Fanapt | Iloperidone | 75 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 74 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 72 | 11 |
| Clonidine Hcl | Clonidine Hcl | 65 | suppressed |
| Mirtazapine | Mirtazapine | 65 | 11 |
| Rexulti | Brexpiprazole | 65 | suppressed |
| Topiramate | Topiramate | 64 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 61 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 58 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 58 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 57 | suppressed |
| Paliperidone Er | Paliperidone | 57 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 56 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 49 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 48 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 41 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Carbamazepine Er | Carbamazepine | 37 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 34 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 26 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Caplyta | Lumateperone Tosylate | 25 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Loreev Xr | Lorazepam | 20 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Aristada | Aripiprazole Lauroxil | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Risperidone Odt | Risperidone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,580.32 · 249 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, ERZOFRI EXTENDED-RELEASE, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, LOREEV XR, LYBALVI, Qelbree, REXULTI, SUBLOCADE, UZEDY, VRAYLAR, Zubsolv | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error